We Design
We apply our unique collective expertise to design small molecule therapeutics.
Breakthrough
We push the leading edge to solve drug discovery’s big challenges.
Medicines
We strive to develop meaningful medicines for patients.

Over more than a decade of pioneering technologically-driven methods of drug discovery, Nimbus has used cutting-edge tools to make therapeutic progress against the most challenging of targets — successfully drugging the undruggable, mapping the uncrystallizable and advancing multiple innovative therapeutics to the clinic.

Nimbus Leadership

Annie C. Chen
M.D., M.P.H.

Chief Medical Officer & President of Tyk2 Subsidiary

Alan Collis
Ph.D.

Senior Vice President of Preclinical Development

Erin Cowhig

Chief People Officer

Scott Edmondson
Ph.D.

Senior Vice President, Head of Chemistry

Abbas Kazimi

Chief Business Officer

Jeb Keiper, M.S., MBA

Chief Executive Officer

Christine Loh
Ph.D.

Senior Vice President, Head of Biology

Peter J. Tummino
Ph.D.

Chief Scientific Officer

Holly Whittemore
CPA

Chief Financial Officer

Board of Directors

Bruce Booth, Ph.D.

General Partner, Atlas Venture

Read bio
Jean George, MBA

General Partner, Lightstone Ventures

Read bio
Laura Stoppel, Ph.D.

Analyst, RA Capital Management

Read bio
Rajeev Dadoo, Ph.D., MBA

Partner, SR One Ltd.

Read bio
Steve Hall, Ph.D.

General Partner, Lilly Ventures

Read bio
Mark Iwicki

Chairman and CEO, Kala Pharmaceuticals

Read bio
Nikola Trbovic, Ph.D.

Partner, Pfizer Ventures

Read bio
Jeb Keiper, M.S., MBA

CEO, Nimbus Therapeutics

Read bio
George P. Vlasuk, Ph.D.

President and CSO, Navitor Pharmaceuticals

Read bio

Investors

Nimbus Therapeutics is backed by world-class life science investors, including Atlas Venture, SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, Lightstone Ventures, RA Capital and BVF Partners. The company closed a $24 million Series A financing in June 2011, a $43 million Series B financing in March 2015, an additional $65 million in financing in June 2018 and another $60 million in financing in October 2020.